Company profile
| Company | AiCuris
GmbH & Co.KG |
| Location | Wuppertal, Germany |
| Business model | discovery, research and development of novel antiviral and antibacterial agents for the treatment of severe and potentially life-threatening infectious diseases caused by HCMV, HSV, HIV, hepatitis B and C, and nosocomial bacterial infections |
| Technologies/Targets | Reversed genomics |
| Status | Discovery, Preclinic, Phase I, Phase II |
| Cooperate partners | e.g. Bayer HealthCare, Evotec and 4SC |
| Unpartnered Programms |
10 Clinical programs |
| Funds raised | On April 14, 2010 - AiCuris, has completed its second round of financing by raising 55 Mio Euro (75 Mio US Dollar) from the existing shareholders. |
| Venture investors | Drs. Strüngmann, Santo Holding |
| Number of employees | 60 |
| Contact/Function | Prof. Dr. Helga Rübsamen-Schaeff, CEO |
AiCuris is a pharmaceutical company focused on the discovery, research and development of novel antiviral and antibacterial agents for the treatment of severe and potentially life-threatening infectious diseases. AiCuris has its roots in Bayer's long history of successful anti-infective drugs. Spun out in 2006 AiCuris owns a broad portfolio of R&D programms, compounds and intellectual property which have been transferred.
For further information, please click here: www.aicuris.com